Xeris Biopharma Holdings (XERS) Balance Sheet: Assets & Liabilities

Xeris Biopharma Holdings (XERS) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Xeris Biopharma Holdings reported total assets of $383.53M and total liabilities of $369.84M. Shareholders' equity was $13.69M. Total debt stood at $226.57M against $111.04M in cash and short-term investments, a net debt position of $115.53M. That puts debt-to-equity at 16.55.

Xeris Biopharma Holdings Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Xeris Biopharma Holdings, Inc. (XERS) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Current Assets
Cash and Cash Equivalents	111.04	71.62	67.45	121.97	67.27	37.60	19.52	45.72	42.05
Short-Term Investments	0.00	0.00	5.00	0.00	35.16	96.19	56.03	66.92	0.00
Cash & Short-Term Investments	111.04	71.62	72.45	121.97	102.43	133.79	75.55	112.63	42.05
Accounts Receivable	51.05	40.42	39.20	30.83	17.46	6.88	4.69	2.87	1.20
Inventory	68.67	48.18	38.84	24.74	18.12	8.35	2.18	0.00	0.00
Other Current Assets	9.55	7.45	5.78	9.29	4.59	3.20	5.07	2.40	0.81
Total Current Assets	240.31	167.66	156.26	186.82	142.60	152.21	87.48	117.90	44.05
Non-Current Assets
Property, Plant & Equipment (Net)	27.06	28.21	29.18	9.51	6.63	6.71	7.85	2.03	0.79
Long-Term Investments	0.00	4.12	0.00	0.00	0.00	0.00	13.23	0.00	0.00
Goodwill	22.86	22.86	22.86	22.86	22.86	0.00	0.00	0.00	0.00
Intangible Assets	88.08	98.92	109.76	120.61	131.45	0.00	0.00	0.00	0.00
Other Non-Current Assets	5.22	-4.81	4.54	4.73	0.83	0.23	0.42	0.10	0.16
Total Non-Current Assets	143.21	155.40	166.34	157.70	161.77	6.94	21.50	2.13	0.95
Total Assets	383.53	323.06	322.60	344.52	304.36	159.15	108.99	120.03	45.00
Current Liabilities
Accounts Payable	3.08	2.29	11.57	4.61	8.92	3.12	5.60	0.87	1.98
Short-Term Debt	6.23	21.18	3.50	1.58	0.00	0.00	0.00	0.00	0.00
Current Portion of Long-Term Debt	-	15.10	-	-	-	-	-	-	-
Accrued Liabilities	95.38	37.22	36.35	40.20	44.49	21.07	-	-	-
Deferred Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.23	0.23
Other Current Liabilities	4.89	76.97	80.13	2.66	1.99	4.02	21.74	9.31	2.88
Total Current Liabilities	109.57	100.44	95.19	73.62	79.04	28.21	27.34	10.17	4.86
Non-Current Liabilities
Long-Term Debt	220.34	250.27	225.70	187.08	88.07	87.02	58.31	31.89	0.00
Deferred Tax Liabilities	0.00	0.00	2.27	3.52	4.94	0.00	0.00	0.00	0.00
Other Non-Current Liabilities	8.40	1.97	6.23	25.72	30.20	10.16	8.91	2.56	97.97
Total Non-Current Liabilities	260.26	252.23	234.19	225.71	130.09	97.18	67.21	34.45	97.97
Total Liabilities	369.84	352.68	329.38	299.34	209.13	125.39	94.55	44.62	102.83
Stockholders' Equity
Common Stock	0.02	0.02	0.01	0.01	0.01	0.01	0.00	0.00	0.00
Retained Earnings	-671.31	-671.86	-617.03	-554.77	-460.11	-337.39	-246.25	-120.67	-60.59
Accumulated Other Comprehensive Income	-0.03	-0.03	-0.03	-0.02	-0.03	0.01	0.04	-0.05	-0.44
Additional Paid-in Capital	685.00	642.26	610.25	599.97	555.36	371.13	260.64	196.12	-97.44
Shares Outstanding	166.22	149.43	138.13	136.27	124.87	-	-	-	-
Total Stockholders' Equity	13.69	-29.62	-6.78	45.19	95.23	33.76	14.44	75.41	-57.83
Total Liabilities & Equity	383.53	323.06	322.60	344.52	304.36	159.15	108.99	120.03	45.00

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Xeris Biopharma Holdings Balance Sheet

How much debt does Xeris Biopharma Holdings have?

Xeris Biopharma Holdings had total debt of $226.57M as of Dec 31, 2025, against $111.04M in cash and short-term investments. Its debt-to-equity ratio was 16.55. Total debt was $271.45M a year earlier.

What are Xeris Biopharma Holdings's total assets?

Xeris Biopharma Holdings reported total assets of $383.53M as of Dec 31, 2025, up 18.7% from $323.06M a year earlier. Total liabilities were $369.84M.

What is Xeris Biopharma Holdings's shareholders' equity?

Xeris Biopharma Holdings's shareholders' equity was $13.69M as of Dec 31, 2025, or about $0.08 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition